The Wee1 inhibitor adavosertib is the only compound tested in clinical trials, including several studies in HNSCC, either as monotherapy or in combination with conventional chemotherapy and radiation (NCT04460937, NCT03028766) [177]. The gene discussed is WEE1; the disease is head and neck squamous cell carcinoma.